Related Experiment Videos
[Microtubules and antineoplastic drugs]
1Dept. of Medical Oncology, National Cancer Center Central Hospital, Tokyo, Japan.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|April 1, 1994
Summary
Microtubules are key cell structures and cancer drug targets. New agents like vinorelbine and taxanes offer improved efficacy and reduced toxicity, though resistance mechanisms exist.
Area of Science:
- Cell Biology
- Pharmacology
- Oncology
Background:
- Microtubules, polymerized tubulin, are vital for cell structure, division, and transport.
- Microtubules are established targets for cancer chemotherapy.
- Novel agents are being developed to overcome limitations of existing therapies.
Purpose of the Study:
- To review current and emerging microtubule-targeting agents in cancer therapy.
- To highlight the mechanisms of action and clinical progress of these drugs.
- To discuss resistance mechanisms to microtubule-acting drugs.
Main Methods:
- Review of preclinical and clinical data on microtubule-targeting agents.
- Analysis of drug mechanisms, including depolymerization and stabilization of microtubules.
- Examination of drug combinations and resistance pathways.
Main Results:
- Vinca alkaloids (e.g., vinorelbine) depolymerize microtubules with reduced neurotoxicity.
- Estramustine combined with vinblastine shows efficacy in prostate cancer.
- Taxanes (paclitaxel, taxotere) stabilize microtubules, showing promise in various cancers.
- Rhizoxin acts similarly to vinca alkaloids.
- Resistance can occur via P-glycoprotein or tubulin mutation.
Conclusions:
- Microtubule-targeting agents represent a significant class of anticancer drugs.
- Ongoing research focuses on novel agents, combinations, and overcoming resistance.
- These agents, including vinca alkaloids and taxanes, are crucial in cancer treatment strategies.